Company
Headquarters: Melbourne, VIC, Australia
CEO: Mr. Marjan Mikel B.Sc., M.A.I.C.D.
A$29.7 Million
AUD as of Jan. 1, 2024
US$20.2 Million
Company | Market Cap (USD) |
---|---|
Abbott | $192.67 B |
Stryker Corporation | $113.24 B |
Medtronic | $111.60 B |
Boston Scientific Corporation | $85.22 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia and Israel. The company develops, produces, and sells mobile health applications. Its products include Wheezo, an asthma management tool to help user understand their asthma by providing information, such as triggers, symptoms, medication usage, and other events. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Respiri Limited has the following listings and related stock indices.
Stock: ASX: RSH wb_incandescent
Stock: OTC: KMLXF wb_incandescent